EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bicycle Therapeutics's enterprise value is $458.32 Mil.
Bicycle Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-156.52 Mil. Therefore, Bicycle Therapeutics's EV-to-EBITDA for today is -2.93.
The historical rank and industry rank for Bicycle Therapeutics's EV-to-EBITDA or its related term are showing as below:
BCYC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.48 Med: -4.66 Max: 2.28
Current: -2.93
During the past 7 years, the highest EV-to-EBITDA of Bicycle Therapeutics was 2.28. The lowest was -21.48. And the median was -4.66.
BCYC's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.49
vs BCYC: -2.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Bicycle Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Bicycle Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bicycle Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Bicycle Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's EV-to-EBITDA falls into.
Bicycle Therapeutics's current Enterprise Value is $458.32 Mil.
Bicycle Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-156.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bicycle Therapeutics's PE Ratio for today is calculated as:
Bicycle Therapeutics's share price for today is $22.89.
Bicycle Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Bicycle Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Bicycle Therapeutics (Bicycle Therapeutics) Business Description
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCYC has been successfully added to your 